ccr7

CCR7 Ligand 1 (CCR7-Cmp2105) is an allosteric ligand and antagonist for human CC chemokine receptor 7 (CCR7) with a Kd of 3 nM. This thiadiazole-dioxide ligand suppresses arrestin binding in response to activation by CCL19 with an IC50 of 7.3 μM.

CCR6 inhibitor 1 is an effective and selective inhibitor of CCR6 (IC50 of monkey and human CCR6 was 0.45 nM and 6 nM, respectively). CCR6 is associated with both autoimmune and non-autoimmune diseases, so CCR6 inhibitor 1 is useful for in vitro and in vivo pathophysiology studies as a small molecule inhibitor of CCR6.

CXCR2/CCR7 antagonist-1 (compound 6) is a potent dual antagonist of CXCR2 and CCR7, with IC50 values of 0.0046 μM and 0.0014 μM, respectively. It is valuable for research in tumor metastasis and autoimmune diseases.

CCR7 antagonist1 (30c) functions as a dual antagonist, targeting CXCR2 with an IC50 of 11.02 μM and CCR7 with an IC50 of 0.43 μM.

Cosalane (NSC 658586) is an HIV replication inhibitor, an inhibitor of chemokine receptor 7 (CCR7) signalling in humans and mice, with antiviral activity that blocks the binding of CCR7 to its natural ligands, CCL19 and CCL21.

SLW131 (Compound 10) is a CCR7 antagonist with strong affinity, showing a Ki of 9.85 nM. It inhibits CCL19-induced Go protein activation with an IC50 of 29.4 μM and β-arrestin2 recruitment with an IC50 of 6.0 μM. SLW131 also suppresses CCL19-induced morphological changes in primary BMDC cells and CCR7-mediated migration of mouse CD4+ T cells.

R707 is a humanized monoclonal antibody expressed in CHO cells targeting C-C chemokine receptor type 7 (CCR7/CD197). R707 specifically binds to CCR7, blocking its interaction with ligands CCL19 and CCL21. This blockade inhibits CCR7-mediated cell migration, chemotaxis, and lymphocyte homing to lymph nodes. It exhibits significant biological activity in researching chronic lymphocytic leukemia (CLL), autoimmune diseases, and lymph node metastasis of tumor cells.

CAP-100 is a monoclonal antibody targeting CCR7. It neutralizes the ligand binding site and signaling of CCR7. This compound effectively inhibits migration, extravasation, homing, and survival in chronic lymphocytic leukemia (CLL) samples induced by CCR7. CAP-100 can mediate potent tumor cell killing through host immune mechanisms and exhibits favorable toxicity profiles in related hematopoietic cell subsets. It is involved in research on antitumor activity and diseases like chronic lymphocytic leukemia (CLL).

Potent and selective KV1.3 channel blocker (IC50 values are 0.0019 and 0.65 nM for KV1.3 and KV1.1, respectively). Inhibits CD4+ CCR7- T cell activation. Ameliorates rat experimental autoimmune encephalomyelitis, in a model for multiple sclerosis.